智通财经APP讯，昭衍新药(603127.SH)发布2024年年度报告，报告期内，公司实现营业收入20.18亿元，同比下降15.07%。实现归属于上市公司股东的净利润7407.54万元，同比下降81.34%。实现归属于上市公司股东的扣除非经常性损益的净利润2357.34万元，同比下降93.02%。基本每股收益为0.1元。拟向全体股东每10股派发现金红利0.3元(含税)。
在报告期内，公司整体在手订单金额约为人民币22亿元，签署订单金额约为人民币18.4亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.